Sriram

Urupaanar - authenticity in their performance. My fav-in "Madhiyin Mudhugil" they introduce two harps that sound amazing, except for some reverb issues. Listen, enjoy! @urupaanar" target="_blank" rel="nofollow noopener">youtube.com/@urupaanar via @YouTube

@doctorveera While still early, EARLY-PREG samples collected could be a good resource to validate these findings. Esp. longitudinal sampling from the same donor might shed light on biological variability. medrxiv.org/content/10.110…

A fascinating investigation of plasma proteomic changes during human menstrual cycle using UK Biobank data. One thing that excites me the most about the current proteomics era is they are going to revolutionize biomarkers discovery, which will have impact across many domains of medicine. More than the proteins -> phenotype, it's phenotype (disease or trait) -> proteins is what appears more exciting, with many medical applications on the horizon. Here is a proteome score based on 75 proteins that predicts the phase of menstrual cycle with a correlation (r) of 0.56, which is pretty impressive for a single snapshot (which will only improve over time) Riishede et al. Nat Med nature.com/articles/s4159…

@TheMarkFdn @andri_lemarquis

Do you know an early-career scientist pushing the boundaries of cancer research?🧬 Our Emerging Leader Award offers $1M in #researchfunding to investigators worldwide. Tag a colleague or share this post to help us spread the word! LOI deadline is April 30. themarkfoundation.org/emerging-leade…

@hereisramji Lmk if you need help with this.

Interested in cohosting / cosponsoring a 15-20 person Chief Scientist dinner in the bay area? DM!

@design_proteins pubmed.ncbi.nlm.nih.gov/15915536/

@vesriram That sounds like a great project! Did you publish your findings, would love to read

Biology is so cool, reading about Sphingomonas paucimobilis' ability to make gellan gum and now I can't stop thinking about engineering it to produce the sweet protein brazzein and making low calorie BioGummies

@stanleyqilab @NatureCellBio @xinyi @czbiohub Max Krummel @MaxKrummel and @amycfanphd were working on a similar cell nibbling phenomenon in a different context.

Ever heard of 'cellular nibbling'? In our @NatureCellBio paper, we’ve turned trogocytosis into a delivery tool for programmable medicine. Congrats to @Xinyi and team! Link: rdcu.be/fa90i @StanfordBioE @StanfordChEMH @CZBiohub #GeneTherapy #SyntheticBiology

@TwistBioscience AATGAAGTTG AACGTGGTCA AAATAATGCT GGTATTGTTG AAGTTGTTCC TAATGAAGTT GAACGTGGTC AAAATAATGC TTTAGAAACT GTTGATCAAT GGAATAATGA AGTTGAACGT GGTCAAAATA ATGCTCGTGT TAATGCTCGT CAAGTTAATG ATGCTAATGA TGATGAATCT GAACGTACTG TT

@TwistBioscience NEVER GONNA GIVE YOU UP.  NEVER GONNA LET YOU DOWN. NEVER GONNA RUN AROUND AND DESERT YOU

AATGAGGTCGAGAGAGGTCAGAATAATGCGGGTATTGTCGAGTACCAGGTAGTACCCTGAAATGAGGTCGAGAGAGGTCAGAATAATGCGCTGGAGACTTACCAGGTAGATCAGTGGAATTGAAATGAGGTCGAGAGAGGTCAGAATAATGCGAGGGTCAATGCGAGACAGGTAAATGATGCGAATGATGATGAGTCCGAGAGAACTTACCAGGTA @TwistBioscience

I often get surprised when I meet someone new and realize they’ve been quietly following my work here. So sharing this a bit more openly. I’ve started having conversations with people who want to back what we’re building in India 🇮🇳🧬💊 If that’s you, happy to connect.

Really cool opportunity: Google PhD fellowship program provides up to US $85,000 per year to cover tuition, residency & travel and access to a Google Research Mentor You need to get your university/department to nominate you Deadline: April 30, 2026 research.google/programs-and-e…

Huge energy at the @biopioneers event in Berkeley! Honored to celebrate the women leaders & founders shaping the future of Bay Area biotech. If you could sum up their roadmap for success, it looks like this: Courage, resilience, and relentless discipline. #WomensHistoryMonth

@iskander Never mind, got the answer...

@iskander Is lymphodepletion really necessary for this type of therapy?

Interesting study: A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors nature.com/articles/s4146…

@booleanbio @iskander Depends on the program and number of open spots for counter-screen in the assay setup but typically 2

@vesriram @iskander How many do you generally do as a panel of “alike” targets? I’ve been avoiding this because it can get somewhat expensive

Going to test 192 de novo binders against two target proteins + HSA & Hsp90 as negative controls. Are there some particularly sticky common proteins I should add to that control set?

@mbfennjr @SaraNayeem I do the same all the time. I'm well aware of it, people have pointed it out to me a few times but I still end up talking at a fast pace. Even when I deliberately /intentionally slow down, it works for the first few slides..

@SaraNayeem I'm guilty of being the fast talker when giving a pitch... it's a point well taken having seen it sitting on the other side of the table

Recently I was at a dinner with other investors and we were lamenting pitches where there’s a “fast talker”. As a presenter, it’s always good to check yourself to determine if you’re talking at a speed that allows your audience to do several things at once: 1) hear and comprehend what you’re saying; 2) take notes; 3) look at the slide to correlate what you’re saying with the figures there; 4) formulate and ask questions. The speed at which you can transmit information as a person intimately familiar with your slides / data is going to be much faster than someone new to the story can absorb it. The goal should not be to transmit as much information as possible by talking at maximum speed. There is no way to tell investors everything on a one hour call; focus on presenting a cogent argument with enough data to be persuasive, but without so much detail that it’s overwhelming. Make sure there’s time for questions along the way. Note that it’s more important to hit every key point high-level, than it is to go into great detail about certain points (e.g., don’t completely neglect to mention IP, competition, etc., simply to add one more data slide). Another habit to avoid along these lines – talking (or pontificating) for a long period of time on a single slide, particularly when there are other slides in the deck that actually make each of your points. Many people are visual learners, so make full use of the slides you’ve prepared.

Excellent, honest, and useful notes on writing github.com/mnielsen/notes…

So, I can start genuinely saying that I work in NeuroImmunology now instead of just cancer immunology? rdcu.be/e5OWj. We can also understand why beta-blockers improve cancer outcomes in some cases